The metabolic fate of [1-'4C]hexadecyl sulphate and hexadecyl [35S]sulphate, administered intravenously as the sodium and trimethylammonium salt to dogs and orally as the erythromycin salt to dogs, rats and humans, was studied. Studies with rats indicated that the compounds were well absorbed and rapidly excreted in the urine. However, after oral administration of the 14C-and 35S-labelled hexadecyl sulphate erythromycin salt to dogs, considerable amounts of radioactivity were excreted in the faeces as unmetabolized hexadecyl sulphate. Studies with two humans showed that orally administered erythromycin salt of [1-14C] [1-_4C]hexadecyl sulphate was also isolated from the urine of rat, dog and man. However, there was still another metabolite in dog urine, which comprised about 20% of the total urinary radioactivity and carried both 14C and 35S labels. This metabolite was absent from rat urine. The metabolite in dog urine was isolated and subsequently identified by t.l.c. and g.l.c. and by isotope-dilution experiments as the sulphate ester of glycollic acid. Small amounts (about 5 % of the total recovered radioactivity in excreta) of labelled glycollic acid sulphate were also found in human urine after ingestion of erythromycin [1-14C]hexadecyl sulphate.
35S labels. This metabolite was absent from rat urine. The metabolite in dog urine was isolated and subsequently identified by t.l.c. and g.l.c. and by isotope-dilution experiments as the sulphate ester of glycollic acid. Small amounts (about 5 % of the total recovered radioactivity in excreta) of labelled glycollic acid sulphate were also found in human urine after ingestion of erythromycin [1-14C] hexadecyl sulphate.
The surface-active properties ofhexadecyl sulphate have been known since the early days of organic chemistry after hexadecyl hydrogen sulphate and its potassium salt were first prepared by Dumas & Peligot (1836) . Despite the wide use of hexadecyl sulphate as a detergent and foaming agent in industrial and domestic preparations, no metabolic studies in mammals with identification of the products of degradation have been reported. However, Denner et al. (1969) have published results on the metabolism of potassium dodecyl [32S] sulphate in the rat. They identified the main metabolite of dodecyl sulphate in rat urine as the sulphate ester of 4-hydroxybutyric acid. Since dodecyl sulphate is a homologue of hexadecyl sulphate possessing four less carbon atoms, I thought that the metabolic degradation of these two compounds should proceed along similar patterns.
The present investigation is about the metabolism of [1-14C] hexadecyl sulphate and hexadecyl (35S]_ sulphate administered intravenously to dogs and orally to rats, dogs and humans. The ester has been found to be metabolized to butyric acid 4-sulphate as the main product and y-butyrolactone as a minor product in the rat, dog and man. However, in the dog and man, but not in the rat, some ofit is broken down further to glycollic acid sulphate. Vol. 148
MAterials and Methods Labelled drugs
Trimethylammonium salt of [1-14C] hexadecyl sulphate. It was prepared by Mr. Arthur Alter (Abbott Laboratories, North Chicago, Ill., U.S.A.), from labelled palmitic acid (New England Nuclear Corp., Boston, Mass., U.S.A.) by the reduction to hexadecan-1-ol and reaction with S03-trimethylamine complex (Aldrich Chemical Co., Milwaukee, Wis., U.S.A.). It was found both chemically and radiochemically to be at least 95 % pure and had a specific radioactivity of 61.5,Ci/mg. Sodium salt ofhexadecyl [35S] sulphate. It was purchased from The Radiochemical Centre (Amersham, Bucks., U.K.), and had an initial specific radioactivity of 18.75,Ci/mg. The salt was used within 1 month of delivery.
Erythromycin salt of [1-'4C] hexadecyl sulphate.
The salt was synthesized by Mr. Alter by the reaction of trimethylammonium salt of [1-'4C] hexadecyl sulphate with erythromycin A base (Abbott Laboratories). Its purity (>99.5%) was checked by t.l.c. in three different solvent systems, by i.r. and n.m.r. spectrometry, and by an isotopic-dilution technique. Its specific radioactivity was 16.7,uCi/mg. (Purina Lab Chow or Gaines Dog Food) without restriction 6h after dosage. Three rats were kept in controlled-environment metabolism cages (Delmar-Roth, model no. DS-7005) and the expired CO2 was trapped in ethanolamine-ethanol (1:1, v/v).
Sample collection. Urine samples were filtered through a glass-wool plug and, whenever possible, were assayed immediately by t.l.c.; otherwise they were stored frozen at -10°C and assayed not more than 1 week later. Blood samples were withdrawn at designated times from the rat (tail vein) and dog (jugular vein) into heparinized vials. Plasma was separated from cells by centrifugation at lOOOg for 10min.
Human studies
Two adult healthy male human volunteers were in this experiment; subject N.J. Denner et al. (1969) . After cooling, Ba35SO4 was precipitated as described above, T.l.c. Separation of the radioactive metabolites of hexadecyl sulphate, administered in the form of its sodium, trimethylammonium or erythromycin salt, was performed on silica-gel plates in two solvent systems. Solvent mixture A, consisting of acetic acid, water and butan-1-ol (1:1:4, by vol.) has been described by Denner et al. (1969) . Solvent mixture B contained acetic acid, methanol and chloroform (1: 3:16, by vol.). After the plates had been developed (which usually took 4h in solvent A and 1 h in solvent B), 0.5cm sections were sequentially scraped by an automatic scraper (Analabs Co., North Haven, Conn., U.S.A.) into counting vials containing O0ml of methanol-toluene scintillation solution and were assayed for radioactivity. No corrections for quenching were made.
Urine samples could be spotted directly on t.l.c. plates. In some experiments, when' the drug was labelled with 35S, it was desirable to exclude possible inorganic sulphate. In this case, urine samples (3 ml) were freeze-dried and the residue was extracted with 3 x 3 ml of boiling methanol. The combined methanol extracts were centrifuged at 10OOg for 15min and evaporated under N2 to about 1 ml before application to silica-gel plates. Faecal samples were homogenized in aq. 80% (v/v) ethanol and the centrifuged extracts were spotted on silica-gel t.l.c. plates. For the analyses of plasma samples, 2ml portions were freezedried and the residues were extracted with 3 x 3ml of boiling methanol. The combined methanol solutions were centrifuged and evaporated under N2 to about 0.5-Iml for t.l.c. The methanol-extraction residue was suspended in 2ml of water and lOml of Aquasol and the radioactivity of the resulting gel was assayed.
Gas-liquid chromatography. G.l.c. was carried out with a Varian Aerograph series 1400 instrument equipped with a flame ionization detector. Two stainless-steel columns (180cm long, 3.2mm inner diam.) were used: one was packed with 10% (w/w) diethylene glycol adipate on 80-100-mesh Chromosorb Q and operated at 1 10°C; the other column was packed with 40-60-mesh Chromosorb W, coated with 20% (w/w) neopentyl glycol succinate and operated at 100°C or 130°C. The injection-chamber temperature was 220°C and the detector temperature was 2300C. The N2 carrier gas-flow rate was 20ml/min. The columns were connected with a splitter which directed 90% of the gas flow through a stainless-steel tube (50cm long, Vol. 148 2mm diam.). This tubing was encased in 6mm-diam. copper tubing except for 35mm which was protruding, uncovered, from the end of the copper tubing. Heating tape (1.27cm x 122cm; Clas-Col Apparatus Co., Terre Haute, Ind., U.S.A.), was wrapped around the copper tubing and the temperature was kept at 180-200'C. Exciting gases were trapped as they bubbled through lOml of methanol-toluene-based scintillation liquid contained in counting vials. These vials were changed manually every minute, immediately capped and assayed for radioactivity.
Experimental and Results
Recoveries of radioactivities, due to the administered labelled hexadecyl sulphate doses, in 0-48h excreta exceeded 91 % in rats; in dogs they ranged from 79 to 92 % and in humans from 86 to 88 %. Only 3-7% of the oral erythromycin [1-'4C]hexadecyl sulphate dose was expired as "4CO2 in rats. The complete information of the recoveries of excreted radioactivity is shown in Table 1 .
In the 35S-and 14C-labelled erythromycin hexadecyl sulphate molecules both labels are located in the hexadecyl sulphate portion. Therefore assuming complete dissociation of the erythromycin salt in water solution, the radioactivity in the excreta would represent hexadecyl sulphate and/or its metabolites rather than the intact salt, erythromycin hexadecyl sulphate.
Metabolic patterns Plasma. The rapid appearance of radioactivity in plasma of dogs and humans after oral administration of erythromycin [1-_4C]hexadecyl sulphate indicated rapid absorption of the drug. Fig. 1 Faeces. Although the faecal excretion of orally administered labelled dose was negligible in the rat, dogs excreted considerable amounts of radioactivity in the faeces. Further, the elimination of the labelled dose in faeces was rather slow in the dog. The 24-48h faeces contained about 30 % ofthe orally administered 35S dose (dog 6) and 39 % of the 14C dose (dog 8). The urinary elimination of radioactive products from 24 to 48h was relatively small, thus assuring less contamination of faeces. The metabolite patterns ofthese two faecal samples were determined by t.l.c. The results revealed that in the dog all of the faecal radioactivity was due to unmetabolized labelled hexadecyl sulphate. Absorption of orally administered erythromycin salt of [1-_4C]hexadecyl sulphate proceeded differently in the two human subjects used in the experiment. During the 0-48h time-interval, the drug had been relatively well absorbed in subject N.J.V. but poorly absorbed in subject D.J.D. Analysis of the faecal excreta by t.l.c. in two solvent systems revealed that all the faecal radioactivity was due to unmetabolized [1-_4C]hexadecyl sulphate.
Urine. The urinary excretion of the labelled dose occurred primarily during the first 24h in rat, dog and man. Therefore 0-24h urine samples were used for the determination of metabolic patterns of the drug. These patterns are presented for the rat and dog in Fig. 3 To the residue was added 1.6mg of unlabelled potassium butyrate 4-sulphate as a marker and carrier, and the mixture was refluxed for 20h in 15ml of 1 M-HCl. The solution was then shaken with 4 x 20ml of benzene, the pooled benzene solutions were dried over anhydrous Na2SO4 and evaporated in vacuo to about 0.1-0.2ml. A solution of about 2mg of authentic y-butyrolactone in benzene was treated the same way. Fig. 4(a) demonstrates a g.l.c. tracing for y-butyrolactone derived from the potassium butyrate 4-sulphate marker and the main metabolite in dog urine. The y-butyrolactone marker and radioactivity peak emerged at the same time, after 12min, from the 10 % diethylene glycol adipate colunn at 110°C. The authentic y-butyrolactone (Aldrich Chemical Co.) had a retention time of 12imin. Similar results were obtained with rat urine on a diethylene glycol adipate column. On a 20 % neopentyl glycol succinate column at 130°C theretention time ofy-butyrolactone was 12*min and its peak coincided again with the radioactivity peaks derived from dog, rat and human urine. The recoveries of injected radioactivities on both columns were 100%. Thus it can be concluded that the main metabolite of hexadecyl sulphate in the urine ofrat, dog and man was butyric acid 4-sulphate.
Identification of y-butyrolactone. Fig. 3 shows that the tracings of 14C and 35S labels closely followed each other except in two zones. The first zone, with RF 0.05, had a 35S peak representing inorganic sulphate and naturally no 14C radioactivity was expected here. The 35S-labelled peak was absent when a methanol extract of freeze-dried urine was chromatographed. The second zone, with RF in the range 0.7-0.8, contained a relatively small 355 peak which was overshadowed by a bigger 14C peak. Hexadecyl sulphate and y-butyrolactone chromatographed in this zone. Since separation of these two substances in solvent system A was not obtained, solvent system B was used for quantifications ofthese two compounds.
The presence of "4C-labelled y-butyrolactone in rat and dog urine, after oral administration of (1-1"C]-hexadecyl sulphate, was verified by the combination of preparative t.l.c. and g.l.c. techniques. The corresponding zones on silica-gel plates with RF values of 0.65-0.85 in solvent system A were extracted with methanol as described above. The methanol was evaporated in vacuo and the residue was dissolved in 0.1 ml of benzene containing 1mg of y-butyrolactone as a carrier. Then 10,cl of the benzene solution was injected into the gas chromatograph. The radioactivity peak and the tracing of y-butyrolactone peak emerged at the same time, both having a retention time of 12*min on a 10% diethylene glycol adipate column at 110°C.
In a separate experiment hexadecyl [35S]sulphate metabolites were isolated from dog urine by preparative t.l.c. on silica gel with solvent A. Fractions with Vol. 148 RF values 0.45-0.55 were extracted with methanol as described above. The methanol extract did not contain any inorganic [35S] sulphate as determined by precipitation with BaCl2. However, after acid hydrolysis, all the radioactivity in the sample could be precipitated as Ba35SO4, indicating that the main metabolite appeared as the ester sulphate in dog urine.
Identification of glycollic acid sulphate. Fig. 3 shows that there was a difference between the metabolic patterns of hexadecyl sulphate in urine of rat and dog. Silica-gel thin-layer plates, developed in solvent system A, separated a metabolite (RF 0.20) from dog urine which contained about 20% of the total dog urinary radioactivity. This metabolite was totally absent from rat urine. The RF 0.20 metabolite in dog urine contained both the 14C and 35S labels, which suggested the presence of an intact sulphate ester linkage. It was decided to hydrolyse this suspected sulphate ester linkage and then prepare derivatives ofthe liberated alcohol, suspected to be glycollic acid. For that purpose a silica-gel preparative thinlayer plate was spotted with 0-24h urine from a dog, which had been given orally [1-"4C]hexadecyl sulphate erythromycin salt, and developed in solvent system A. Fractions with RF values between 0.20 and 0.25 were extracted withmethanol as described above, pooled and the methanol was evaporated in vacuo at 25°C. The residue was dissolved in 10ml of 1 M-HCI, refluxed for 20h and the solution was freeze-dried. The residue after freeze-drying was dissolved in 5 ml of water, of which 1.8ml was taken for g.l.c. determination, 3ml was used for isotope-dilution experiments and 0.2ml was used for rechromatography on silicagel plates.
(a) T.l.c. When the hydrolysed material was rechromatographed on silica-gel plates, the radioactive zones (RF 0.43 (b) Isotope-dilution experiments. To the 3ml of water solution containing the suspected [2-14C]-glycollic acid was added 600mg ofunlabelled glycollic acid. The solution was neutralized with 1 M-KOH to pH5 and divided into three equal parts of about 4ml each. To one was added 0.2g of p-nitrobenzyl bromide, to another 0.2g of p-bromophenacyl bromide and to the third 0.2g of p-phenylphenacyl bromide (McElvain, 1949) . The mixtures were refluxed and enough ethanol was added to ensure a homogeneous boiling solution. After boiling for 1 h, the solutions were refrigerated at 4°C overnight. The separated esters were recrystallized from aq. 70% (v/v) ethanol and dried in vacuo over CaCl2. About 2-11 mg was accurately weighed out into IOml ofscintillation solution for radioactivity assay. The rest was recrystallized twice more from aq. 95 % (v/v) (Klebe et al., 1966) , was added. The solution was kept for 1-3min at 50°C and 2pul portions of it were injected into the chromatographic column containing 20% neopentyl glycol succinate on Chromosorb W at 100°C. Fig. 4 shows that the trimethylsilylated glycollic acid marker peak had a retention time of 9;min and the fraction with the highest radioactivity emerged between 9 and 10min. Similarly on a diethylene glycol adipate column at 110°C the trimethylsilylated glycollic acid marker peak coincided with the peak of radioactivity. In both cases the radioactive peak contained more than 80% of the inAjected radioactivity. Composition of metabolites of hexadecyl sulphate in urine of rat, dog and man Table 4 summarizes the RF values of t.l.c. on silica gel for the identified hexadecyl sulphate metabolites and for some related compounds in two solvent systems. These RF values were used for the identification of radioactive peaks on silica-gel chromatograms obtained with rat, dog and human urines. Table 5 .
Discussion
For the separation of metabolites silica-gel t.l.c. was chosen, since silica gel has high capacity for inorganic salts (Donike et al., 1973 The metabolic fate of hexadecyl sulphate was independent of the cation part of the salt, since sodium, trimethylammonium and erythromycin salts produce similar urinary metabolic patterns. The metabolic fate of hexadecyl sulphate was not affected by the route of administration.
The classical experiments by Verkade (Verkade et al., 1933; Verkade & van der Lee, 1934a,b; Verkade et al., 1935 ) suggested co-oxidation as an alternative pathway to the direct fl-oxidation of fatty acids in mammalian tissues. The importance of this pathway is apparent for compounds in which foxidation is blocked by substituents at the a or , carbon: the molecule could be co-oxidized and then ,f-oxidized from the unsubstituted end (Flaschentrager et al., 1934; Bergstr6m et al., 1954) . Enzyme systems involved in the co-oxidation offatty acids and their derivatives have been found in the liver microsomal fraction ofguinea pigs (Wakabayashi & Shimazono, 1963 ) and of rats (Preiss & Bloch, 1964 Denner et al. (1969) . They suggested that the metabolism is initiated by co-oxidation of the terminal methyl group. The resulting substituted fatty acid could then undergo oxidation, analogous to normal fl-oxidation, with the successive elimination of C2 fragments. They found that the final degradation product of dodecyl sulphate in rat was butyric acid 4-sulphate and that for some reason further f-oxidation of this ester to glycollic acid sulphate did not occur. The results of the present investigation of the metabolism of hexadecyl sulphate confirm the conclusion of Denner et al. (1969) that sulphuric acid esters of long-chain fatty alcohols are metabolized in rat to the sulphate ester of 4-hydroxybutyric acid. In the present study the major metabolite ofhexadecyl sulphate in dog and man has also been found to be the sulphate ester of 4-hydroxybutyric acid. However, I found that although further fl-oxidation of butyric acid 4-sulphate in the rat did not occur, some of the 4-hydroxybutyric acid sulphate ester had obviously been further metabolized in the dog and human, so that of the total recovered radioactivity about 20% was associated with glycollic acid sulphate in dog urine and 5 % in human urine. Why the process, by which hexadecyl sulphate is shortened, should stop or slow down at the stage of butyric acid 4-sulphate is not readily apparent. 
